鹿特丹欧洲前列腺癌筛查随机研究第五轮筛查发现的前列腺癌特征:能否通过前置多变量风险分层和磁共振成像选择性检出高级别前列腺癌?
在鹿特丹欧洲前列腺癌筛查随机研究第五轮筛查中,337名71-75岁、前列腺特异性抗原≥3.0 ng/ml的男性接受活检;179人接受六针经直肠超声引导活检,158人接受磁共振成像、12针经直肠超声引导活检及融合靶向活检。基于鹿特丹前列腺癌风险计算器4的前置风险分层联合磁共振成像和经直肠超声引导活检可避免约三分之二的活检和低级别前列腺癌诊断,同时维持与全部经直肠超声引导活检策略相当的高级别前列腺癌检出率。
要点
- 在既往活检过的男性中,高级别前列腺癌检出率为5%,活检初治男性为22%。
- 六针经直肠超声引导活检、12针经直肠超声引导活检和磁共振成像±靶向活检的高级别前列腺癌检出率相似(11%、12%、11%)。
- 基于风险计算器4的分层联合12针经直肠超声引导活检±磁共振成像靶向活检可避免65%的活检和68%的低级别前列腺癌,高级别前列腺癌检出率为83%,而全部经直肠超声引导活检策略为79%。
核心结论
- 在四次重复筛查且半数男性至少一次既往活检后,相当比例71-75岁男性仍患有高级别前列腺癌。
- 前置风险分层联合磁共振成像和经直肠超声引导活检在本队列中可避免三分之二的活检和低级别前列腺癌诊断,同时维持与全部经直肠超声引导活检策略相当的高级别前列腺癌检出。
- 需要进一步研究验证这些结果。
研究设计与样本
- 鹿特丹欧洲前列腺癌筛查随机研究第五轮筛查(71-75岁)中,337名前列腺特异性抗原≥3.0 ng/ml的男性接受活检。
- 179名男性接受六针经直肠超声引导活检,158名男性接受磁共振成像、12针经直肠超声引导活检,并对前列腺影像报告和数据系统≥3的病灶行融合靶向活检。
主要发现
- 55%的男性既往接受过活检。
- 活检初治男性的总体、低级别(格里森评分3+3)和高级别(格里森评分≥3+4)前列腺癌检出率分别为48%、27%和22%。
- 既往活检男性的上述前列腺癌检出率分别为25%、20%和5%。
- 六针经直肠超声引导活检、12针经直肠超声引导活检和磁共振成像±靶向活检的高级别前列腺癌检出率相似(11%、12%、11%),但低级别前列腺癌检出率显著不同(17%、28%、7%)。
- 基于鹿特丹前列腺癌风险计算器4的分层联合12针经直肠超声引导活检±磁共振成像靶向活检与全部经直肠超声引导活检策略相比,可避免65%的活检和68%的低级别前列腺癌,高级别前列腺癌检出率分别为83%和79%。
局限性
- 需要进一步研究验证这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The harm of screening (unnecessary biopsies and overdiagnosis) generally outweighs the benefit of reducing prostate cancer (PCa) mortality in men aged ≥70 yr. Patient selection for biopsy using risk stratification and magnetic resonance imaging (MRI) may improve this benefit-to-harm ratio. OBJECTIVE: To assess the potential of a risk-based strategy including MRI to selectively identify men aged ≥70 yr with high-grade PCa. DESIGN, SETTING, AND PARTICIPANTS: Three hundred and thirty-seven men with prostate-specific antigen ≥3.0 ng/ml at a fifth screening (71-75 yr) in the European Randomized study of Screening for Prostate Cancer Rotterdam were biopsied. One hundred and seventy-nine men received six-core transrectal ultrasound biopsy (TRUS-Bx), while 158 men received MRI, 12-core TRUS-Bx, and fusion TBx in case of Prostate Imaging Reporting and Data System ≥3 lesions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the overall, low-grade (Gleason Score 3+3) and high-grade (Gleason Score ≥ 3+4) PCa rate. Secondary outcome was the low- and high-grade PCa rate detected by six-core TRUS-Bx, 12-core TRUS-Bx, and MRI ± TBx. Tertiary outcome was the reduction of biopsies and low-grade PCa detection by upfront risk stratification with the Rotterdam Prostate Cancer Risk Calculator 4. RESULTS AND LIMITATIONS: Fifty-five percent of men were previously biopsied. The overall, low-grade, and high-grade PCa rates in biopsy naïve men were 48%, 27%, and 22%, respectively. In previously biopsied men these PCa rates were 25%, 20%, and 5%. Sextant TRUS-Bx, 12-core TRUS-Bx, and MRI ± TBx had a similar high-grade PCa rate (11%, 12%, and 11%) but a significantly different low-grade PCa rate (17%, 28%, and 7%). Rotterdam Prostate Cancer Risk Calculator 4-based stratification combined with 12-core TRUS-Bx ± MRI-TBx would have avoided 65% of biopsies and 68% of low-grade PCa while detecting an equal percentage of high-grade PCa (83%) compared with a TRUS-Bx all men approach (79%). CONCLUSIONS: After four repeated screens and ≥1 previous biopsies in half of men, a significant proportion of men aged ≥70 yr still harbor high-grade PCa. Upfront risk stratification and the combination of MRI and TRUS-Bx would have avoided two-thirds of biopsies and low-grade PCa diagnoses in our cohort, while maintaining the high-grade PCa detection of a TRUS-Bx all men approach. Further studies are needed to verify these results. PATIENT SUMMARY: Prostate cancer screening reduces mortality but is accompanied by unnecessary biopsies and overdiagnosis of nonaggressive tumors, especially in repeatedly screened elderly men. To tackle these drawbacks screening should consist of an upfront risk-assessment followed by magnetic resonance imaging and transrectal ultrasound-guided biopsy.
引用
- Alberts AR, Schoots IG, Bokhorst LP, et al. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging? Eur Urol. 2017. PMID: 28647216. doi:10.1016/j.eururo.2017.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。